Liam Davenport December 12, 2024 19 Added to Email Alert The story of antimicrobial peptides (AMPs), particularly in tackling antibiotic resistance, has been one of false dawns and unfulfilled promises. But perhaps a new generation of “smarter” compounds could see them find a wider role in clinical practice, said experts.Henrik Franzyk, MSc Engineering AMPs may...
Category: <span>Research Updates</span>
Post
Unlocking the clock: The role of the circadian system in inflammatory bowel diseases
New insights highlight the potential for circadian clock modulation in IBD treatment per-Reviewed Publication THE HEBREW UNIVERSITY OF JERUSALEM This study highlights the critical role of the body’s circadian clock in regulating immune activity and digestive functions, revealing its influence on the development and progression of inflammatory bowel diseases (IBDs) such as Crohn’s disease and...
Post
The skin’s ‘surprise’ power: it has its very own immune system
The finding could lead to the development of needle-free vaccines. Skin can generate antibodies, independent of the rest of the immune system.Credit: kazuma seki/Getty The skin — once thought to be a mainly passive barrier — can produce its own antibodies that fight off infections, a pair of studies reports in Nature this week1,2. The findings could...
Post
Wearable patch can monitor breathing to help save lives
by Nottingham Trent University Credit: Nottingham Trent University Scientists have developed a wearable patch that can accurately monitor and detect changes in people’s breathing—even when not in direct contact with the skin. It is hoped that the device—thought to be the first of its kind—can be used in health care settings and in the home to...
Post
People with epilepsy have higher likelihood of cognitive impairment
by Elana Gotkine Cognitive impairment, especially in learning and memory, is more likely among people with epilepsy, according to a study published online Nov. 19 in Epilepsia Open. Remy Pugh, from Monash University in Clayton, Australia, and colleagues examined cognitive and psychological compromise in patients diagnosed with epilepsy in a sample of 201 patients referred to the Austin...
Post
Ethyl lactate identified as potential therapeutic for alcohol-associated liver disease
by Liu Jia, Chinese Academy of Sciences The proposed model for nonethanol ingredient ethyl lactate-mediated hepatic FGF21 activation in inhibiting the pathogenesis of ALD in mice. Credit: Advanced Science (2024). DOI: 10.1002/advs.202409516 A research team led by Prof. Li Yu from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences (CAS) and collaborators...
Post
Novel nightmare therapy for children shows promise in clinical trial
by April Wilkerson, University of Oklahoma Credit: Pixabay/CC0 Public Domain Recently published research from the University of Oklahoma and the University of Tulsa shows that a new therapy for children with chronic nightmares reduced the number of nightmares and the distress they caused and increased the number of nights a child slept without waking. The study, published in Frontiers...
Post
Q&A: Interplay between immune cells and HPV keeps skin healthy
by Mass General Brigham Papillomavirus-induced immune response blocks the expansion of mutant cells in sun-damaged skin. A large collection of mutant cells in ultraviolet-radiated skin without papillomavirus colonization (left) compared with a small number of mutant cells surrounded by immune cells in papillomavirus-colonized skin (right). Memory T cells (red), killer T cells (yellow), and mutant skin...
Post
Surrey research suggests new treatment strategy to tackle rare immune disorders
Peer-Reviewed Publication UNIVERSITY OF SURREY Several rare immune disorders are caused by mutations in the patient’s DNA. The University of Surrey and its collaborators found that targeting the mutated pathways with new drugs offers new hope for people suffering from rare conditions such as immunodeficiencies. The multidisciplinary team looked at a genetic mutation called biallelic PI4KA,...
Post
Bovhyaluronidase azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19
Reports and Proceedings MINDSET CONSULTING Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19. Bovhyaluronidase azoximer, marketed under the brand name Longidaza, is a polymer-conjugated hyaluronidase with an extended half-life. The study drug and placebo...